Effect of HIV-infection and menopause status on raltegravir pharmacokinetics in the blood and genital tract

Abstract

This study describes first dose and steady state pharmacokinetics of raltegravir (RAL) in cervicovaginal fluid (CVF) and blood plasma (BP)

    Similar works